公开(公告)号：US20230293719A1

公开(公告)日：2023-09-21

申请号：US17859078

申请日：2022-07-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  In-Cheol SUN ,  Hong Yeol YOON ,  Man Kyu SHIM ,  Suah YANG

IPC: A61K47/69 ,  A61P35/00 ,  A61K47/64

CPC classification number: A61K47/6915 ,  A61K47/64 ,  A61P35/00

Abstract: Disclosed is an optimal peptide-liposome complex capable of multivalent crosslinking with PD-L1 on the cell surface to induce degradation of PD-L1. The peptide-liposome complex effectively blocks PD-L1, an immune checkpoint on the surface of cancer cells, and prevents the recycling of PD-L1 by intracellular metabolism to induce complete degradation of PD-L1 in cancer cells, achieving an increased therapeutic effect on cancer.

公开(公告)号：US20210179681A1

公开(公告)日：2021-06-17

申请号：US17118767

申请日：2020-12-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung KIM ,  Ju Hee RYU ,  Hong Yeol YOON ,  Man Kyu SHIM ,  Suah YANG

IPC: C07K14/47 ,  C07K16/28 ,  A61K47/10 ,  A61P35/00

Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.